Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 6Lymphoid 6Myeloid 2Dermatologic 2Classical hematology 2CNS 2Sarcoma 1Plasma cell 1

Conditions

Oligodendroglioma 1Gliosarcoma 1Glioma 1Glioblastoma 1Central Nervous System Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 62Cyclophosphamide 59Radiotherapy 47Doxorubicin 36Filgrastim 26Irinotecan 24Radiation 23Gemcitabine 23fludarabine 22Magnetic Resonance Spectroscopy 20Imatinib Mesylate 19Etoposide 18pembrolizumab 16Cisplatin 15Carboplatin 15Biopsy 15Bevacizumab 15Specimen Handling 14fludarabine phosphate 12Nivolumab 12Leucovorin 12Ipilimumab 12Granulocyte Colony-Stimulating Factor 12Chemotherapy, Adjuvant 12pazopanib 11Vincristine 11Ifosfamide 11Melphalan 10Erlotinib Hydrochloride 10Docetaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × laromustine × Sarcoma × Clear all
NCT00516282 2011-08-26

VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma

Northwestern University

Phase 1 Terminated
14 enrolled
CNSSarcoma

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡